Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 189

1.

Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials.

VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group, D'Amico DJ, Masonson HN, Patel M, Adamis AP, Cunningham ET Jr, Guyer DR, Katz B.

Ophthalmology. 2006 Jun;113(6):992-1001.e6. Epub 2006 Apr 27.

PMID:
16647134
2.

Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration.

VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group, Chakravarthy U, Adamis AP, Cunningham ET Jr, Goldbaum M, Guyer DR, Katz B, Patel M.

Ophthalmology. 2006 Sep;113(9):1508.e1-25. Epub 2006 Jul 7.

PMID:
16828500
3.

Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration.

Macugen AMD Study Group, Apte RS, Modi M, Masonson H, Patel M, Whitfield L, Adamis AP.

Ophthalmology. 2007 Sep;114(9):1702-12. Epub 2007 May 23.

PMID:
17509689
4.

Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial.

Singerman LJ, Masonson H, Patel M, Adamis AP, Buggage R, Cunningham E, Goldbaum M, Katz B, Guyer D.

Br J Ophthalmol. 2008 Dec;92(12):1606-11. doi: 10.1136/bjo.2007.132597. Epub 2008 Jul 9.

5.

Pegaptanib for neovascular age-related macular degeneration.

Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group.

N Engl J Med. 2004 Dec 30;351(27):2805-16.

6.

Pegaptanib sodium for the treatment of neovascular age-related macular degeneration: a review.

Kourlas H, Schiller DS.

Clin Ther. 2006 Jan;28(1):36-44. Review.

PMID:
16490578
7.

Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review.

Takeda AL, Colquitt J, Clegg AJ, Jones J.

Br J Ophthalmol. 2007 Sep;91(9):1177-82. Epub 2007 May 2. Review.

8.

Pegaptanib: in exudative age-related macular degeneration.

Siddiqui MA, Keating GM.

Drugs. 2005;65(11):1571-7; discussion 1578-9. Review.

PMID:
16033295
9.

[Clinical experience in the treatment of neovascular age-related macular degeneration with pegaptanib].

Maier M, Feucht N, Huebner M, Lohmann C.

Klin Monbl Augenheilkd. 2008 Jun;225(6):582-7. doi: 10.1055/s-2008-1027474. German.

PMID:
18516780
10.

Treatment of naïve lesions in neovascular age-related macular degeneration with pegaptanib.

Quiram PA, Hassan TS, Williams GA.

Retina. 2007 Sep;27(7):851-6.

PMID:
17891008
11.

Pegaptanib sodium for occult choroidal neovascularization in neovascular age-related macular degeneration: a prospective case series.

Atmani K, Coscas F, Coscas G, Soubrane G.

Eye (Lond). 2009 May;23(5):1150-4. doi: 10.1038/eye.2008.194. Epub 2008 Jul 18.

PMID:
18636083
12.

Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation.

Colquitt JL, Jones J, Tan SC, Takeda A, Clegg AJ, Price A.

Health Technol Assess. 2008 May;12(16):iii-iv, ix-201. Review.

13.

Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration.

Aisenbrey S, Ziemssen F, Völker M, Gelisken F, Szurman P, Jaissle G, Grisanti S, Bartz-Schmidt KU.

Graefes Arch Clin Exp Ophthalmol. 2007 Jul;245(7):941-8. Epub 2006 Dec 21.

PMID:
17186262
14.

Pegaptanib for neovascular age-related macular degeneration.

Maberley D.

Issues Emerg Health Technol. 2005 Dec;(76):1-4.

PMID:
16544440
15.

[Treatment of neovascular age-related macular degeneration with intravitreal vascular endothelial growth factor inhibitor--secondary publication].

Larsen M, Sander B, Villumsen JE, Haamann PH, la Cour M, Lund-Andersen H; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group.

Ugeskr Laeger. 2005 Aug 29;167(35):3301-5. Danish.

PMID:
16138974
16.
17.

Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis.

Gonzales CR; VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group.

Retina. 2005 Oct-Nov;25(7):815-27.

PMID:
16205558
18.

Pegaptanib for choroidal neovascularization in treatment-naïve exudative age-related macular degeneration.

Ehlers JP, Fintak DR, Gupta OP, Regillo CD, Fineman MS, Ho AC.

Ophthalmic Surg Lasers Imaging. 2007 Sep-Oct;38(5):371-7.

PMID:
17955841
19.

Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study.

Tufail A, Patel PJ, Egan C, Hykin P, da Cruz L, Gregor Z, Dowler J, Majid MA, Bailey C, Mohamed Q, Johnston R, Bunce C, Xing W; ABC Trial Investigators.

BMJ. 2010 Jun 9;340:c2459. doi: 10.1136/bmj.c2459.

PMID:
20538634
20.

A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema.

Cunningham ET Jr, Adamis AP, Altaweel M, Aiello LP, Bressler NM, D'Amico DJ, Goldbaum M, Guyer DR, Katz B, Patel M, Schwartz SD; Macugen Diabetic Retinopathy Study Group.

Ophthalmology. 2005 Oct;112(10):1747-57.

PMID:
16154196

Supplemental Content

Support Center